Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanismsDNTH312 demonstrated
Dianthus Therapeutics created a new medicine candidate for autoimmune diseases and plans to test it in people by the end of 2027. When a company announces new medicines in development, it shows they're working on their future, but we'll need to wait years to see if it actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.